Skip to content
10-Q

Quarterly Report

CATALYST PHARMACEUTICALS, INC. CPRX

0001369568-26-000002

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 122.38M sh
Shares Diluted Q1 2026 · Mar 31, 2026 126.9M sh
Shares Diluted Q1 2026 · Mar 31, 2025 126.96M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $14.57M
Capex Q1 2026 · Mar 31, 2026 $27K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 $59.59M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $60.04M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $755.86M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $709.17M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.01B
Stockholders Equity Q1 2026 · Dec 31, 2025 $954.27M
Stockholders Equity Q1 2026 · Mar 31, 2025 $794.28M
Stockholders Equity Q1 2026 · Dec 31, 2024 $727.63M
Current Liabilities Q1 2026 · Mar 31, 2026 $132.4M
Current Liabilities Q1 2026 · Dec 31, 2025 $147.15M
Total Liabilities Q1 2026 · Mar 31, 2026 $134.91M
Total Liabilities Q1 2026 · Dec 31, 2025 $149.71M
Current Assets Q1 2026 · Mar 31, 2026 $940.39M
Current Assets Q1 2026 · Dec 31, 2025 $894.03M
Total Assets Q1 2026 · Mar 31, 2026 $1.15B
Total Assets Q1 2026 · Dec 31, 2025 $1.1B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.50
Eps Diluted Q1 2026 · Mar 31, 2025 $0.45
Eps Basic Q1 2026 · Mar 31, 2026 $0.52
Eps Basic Q1 2026 · Mar 31, 2025 $0.47
Sga Expense Q1 2026 · Mar 31, 2026 $49.32M
Sga Expense Q1 2026 · Mar 31, 2025 $46.91M
Rd Expense Q1 2026 · Mar 31, 2026 $2.66M
Rd Expense Q1 2026 · Mar 31, 2025 $3.89M
Net Income Q1 2026 · Mar 31, 2026 $63.73M
Net Income Q1 2026 · Mar 31, 2025 $56.74M
Operating Income Q1 2026 · Mar 31, 2026 $73.23M
Operating Income Q1 2026 · Mar 31, 2025 $63.37M
Revenue Q1 2026 · Mar 31, 2026 $149.39M
Revenue Q1 2026 · Mar 31, 2025 $141.42M